DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

ImmunoGen (NASDAQ: IMGN)

6.11 -4.74 (-43.69%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

IMGN $6.11 -43.69%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.97
Previous Close $10.85
Daily Range $5.36 - $6.82
52-Week Range $5.36 - $17.80
Market Cap $525.1M
P/E Ratio -11.30
Dividend (Yield) $0.00 (0.0%)
Volume 16,583,320
Average Daily Volume 1,066,456
Current FY EPS -$0.71





ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website:

News & Commentary Rss Feed

Why ImmunoGen Inc. Stock Was Throttled

ImmunoGen shares lose half their value following an update on a key breast cancer drug trial. Find out whether today's swoon could mark a buying opportunity.

The 52-Week Low Club for Friday

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More

Mid-Day Losers From December 19: ImmunoGen, NQ Mobile And More

Top 3 Short Ideas Among Friday's Losers

ImmunoGen Enters Oversold Territory (IMGN)

Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half

Roche hit by failure of trial for cancer drug Kadcyla

ImmunoGen Reports Encouraging Data on Cancer Drug - Analyst Blog

Insider Trading Alert - UNT, IMGN And PSXP Traded By Insiders

See More IMGN News...

IMGN's Top Competitors

IMGN $6.11 (-43.69%)
Current stock: IMGN
AMGN $170.17 (1.00%)
Current stock: AMGN
GILD $108.45 (2.76%)
Current stock: GILD
BIIB $360.67 (1.97%)
Current stock: BIIB